James A. Roper

University Walk
Bristol, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

An Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 Inhibitor.

An Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 Inhibitor.

Journal: Journal of medicinal chemistry

Published: April 29, 2026

Physiological, patho-physiological, and potential therapeutic roles for neutrophils in cancer & beyond.

Physiological, patho-physiological, and potential therapeutic roles for neutrophils in cancer & beyond.

Journal: Frontiers in immunology

Published: December 03, 2025

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

Journal: Haematologica

Published: September 08, 2025

Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of Cancer.

Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of Cancer.

Journal: Journal of medicinal chemistry

Published: December 12, 2024

Core Modifications of GSK3335103 toward Orally Bioavailable αvβ6 Inhibitors with Improved Synthetic Tractability.

Core Modifications of GSK3335103 toward Orally Bioavailable αvβ6 Inhibitors with Improved Synthetic Tractability.

Journal: Journal of medicinal chemistry

Published: October 17, 2024

Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells.

Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells.

Journal: International journal of molecular sciences

Published: September 21, 2024

Pharmacological Characterization of GB1908, a Selective Galectin-1 Carbohydrate Binding Domain Inhibitor for the Treatment of Cancer.

Pharmacological Characterization of GB1908, a Selective Galectin-1 Carbohydrate Binding Domain Inhibitor for the Treatment of Cancer.

Journal: Pharmacology

Published: July 24, 2024

Inhibition of EphA2 by syndecan-4 in wounded skin regulates clustering of fibroblasts.

Inhibition of EphA2 by syndecan-4 in wounded skin regulates clustering of fibroblasts.

Journal: Journal of molecular cell biology

Published: June 03, 2024

Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer.

Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer.

Journal: Journal of medicinal chemistry

Published: May 28, 2024

A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors.

A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors.

Journal: International journal of molecular sciences

Published: April 30, 2024

Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver.

Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver.

Journal: European journal of pharmacology

Published: April 24, 2024

Determining the Affinity and Kinetics of Small Molecule Inhibitors of Galectin-1 Using Surface Plasmon Resonance.

Determining the Affinity and Kinetics of Small Molecule Inhibitors of Galectin-1 Using Surface Plasmon Resonance.

Journal: International journal of molecular sciences

Published: April 15, 2024

Showing 1-12 of 27

Last Updated: 09/26/2026